Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion
暂无分享,去创建一个
[1] R. Weinshilboum,et al. Olsalazine and 6‐mercaptopurine‐related bone marrow suppression: A possible drug‐drug interaction , 1997, Clinical pharmacology and therapeutics.
[2] W. Reiss,et al. Changes in Interleukin-6 Concentrations following Epilepsy Surgery: Potential Influence on Carbamazepine Phannacokinetics , 1996, The Annals of pharmacotherapy.
[3] S. Arfin,et al. The sequence of porcine protein NH2-terminal asparagine amidohydrolase. A new component of the N-end Rule pathway. , 1995, The Journal of biological chemistry.
[4] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[5] Hongbing Wang,et al. Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.
[6] P. Watkins,et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[7] R. Weinshilboum,et al. Erratum: Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction (Clinical Pharmacology and Therapeutics (1997) 62 (464-475)) , 2000 .
[8] D. Shen,et al. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[9] M. Nikolova-Karakashian,et al. Regulation of Cytochrome P450 2C11 (CYP2C11) Gene Expression by Interleukin-1, Sphingomyelin Hydrolysis, and Ceramides in Rat Hepatocytes (*) , 1995, The Journal of Biological Chemistry.
[10] L. Harries,et al. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[11] R. Gugler,et al. Effects of Antacids on the Clinical Pharmacokinetics of Drugs , 1990, Clinical pharmacokinetics.
[12] R. Stewart,et al. Clinically desirable drug interactions. , 1985, Annual review of pharmacology and toxicology.
[13] K. Carroll,et al. Influence of extracellular matrix overlay and medium formulation on the induction of cytochrome P-450 2B enzymes in primary cultures of rat hepatocytes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[14] I. Yano,et al. Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1. , 1998, The Journal of pharmacology and experimental therapeutics.
[15] C. Peloquin,et al. Effect of Grapefruit Juice on Clarithromycin Pharmacokinetics , 1998, Antimicrobial Agents and Chemotherapy.
[16] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[17] S. Levy,et al. The challenge of antibiotic resistance. , 1998, Scientific American.
[18] S. Jamieson,et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. , 1985, Transplantation.
[19] C. Metroka,et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. , 1991, The New England journal of medicine.
[20] P. Beaune,et al. The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. , 1995, Gastroenterology.
[21] R. Yumoto,et al. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. , 1998, European journal of pharmacology.
[22] H. Lipp,et al. Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins (PCDDs) and their constituents in human HepG2 cells , 2005, Archives of Toxicology.
[23] K. Chan,et al. Decrease in the activity of the drug-metabolizing enzymes of rat liver following the administration of tilorone hydrochloride. , 1976, Drug metabolism and disposition: the biological fate of chemicals.
[24] P. Ghezzi,et al. Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. , 1995, European journal of pharmacology.
[25] Cheng Cheng,et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype , 2006, Clinical pharmacology and therapeutics.
[26] T. Vales,et al. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. , 1994, Biochimica et biophysica acta.
[27] E. Tanaka,et al. Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.
[28] J. Kampmann,et al. Effect of some drugs on penicillin half‐life in blood , 1972, Clinical pharmacology and therapeutics.
[29] K. Thummel,et al. In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.
[30] H K Kroemer,et al. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.
[31] J. Huneau,et al. Secretion of Sparfloxacin from the Human Intestinal Caco-2 Cell Line Is Altered by P-Glycoprotein Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.
[32] J. Hayes,et al. Regulation of glutathione S-transferases and aldehyde reductase by chemoprotectors: studies of mechanisms responsible for inducible resistance to aflatoxin B1. , 1996, IARC scientific publications.
[33] R. Quintiliani,et al. Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. , 1990, Diagnostic microbiology and infectious disease.
[34] J. Alsenz,et al. Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers , 1998, Pharmaceutical Research.
[35] L. Chauvelot‐Moachon,et al. Acute‐phase response, interleukin‐6, and alteration of cyclosporine pharmacokinetics , 1994, Clinical pharmacology and therapeutics.
[36] S. Sassa,et al. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. , 1992, Biochemical and biophysical research communications.
[37] C. Fletcher,et al. The Effect of Cimetidine and Ranitidine Administration With Zidovudine , 1995, Pharmacotherapy.
[38] D. Greenblatt,et al. Drug interactions with grapefruit juice: an update. , 2001, Journal of clinical psychopharmacology.
[39] J. Gorski,et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.
[40] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[41] A. Somogyi,et al. Pharmacokinetic Interactions of Cimetidine 1987 , 1987, Clinical pharmacokinetics.
[42] M. Picot,et al. Effects of interferon-α on cytochrome P‐450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C , 1998 .
[43] R. Weinshilboum. Sulfotransferase pharmacogenetics. , 1990, Pharmacology & therapeutics.
[44] L. Koymans,et al. P450 inhibitors of use in medical treatment: focus on mechanisms of action. , 1995, Pharmacology & therapeutics.
[45] S. Verma,et al. The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability , 2008, Molecular Pharmacology.
[46] P. Welling,et al. Protein Binding of Antimicrobials: Clinical Pharmacokinetic and Therapeutic Implications , 1977, Clinical pharmacokinetics.
[47] L. Prescott. Clinically Important Drug Interactions , 2012, Drugs.
[48] J. Beijnen,et al. Pharmacokinetic variability of zidovudine in HIV‐infected individuals: subgroup analysis and drug interactions , 1994, AIDS.
[49] Biagio Mazzi,et al. About the Web Site , 2013 .
[50] F. Russel,et al. Saturable Pharmacokinetics in the Renal Excretion of Drugs , 1989, Clinical pharmacokinetics.
[51] C. McClain,et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. , 1994, The Journal of clinical investigation.
[52] F. Guengerich,et al. Role of cytochrome P450 enzymes in drug-drug interactions. , 1997, Advances in pharmacology.
[53] J. Fagan,et al. Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. , 1992, The Journal of biological chemistry.
[54] L. Sansom,et al. What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions? , 1995, Drug safety.
[55] M. Murray. DRUG‐MEDIATED INACTIVATION OF CYTOCHROME P450 , 1997, Clinical and experimental pharmacology & physiology.
[56] M. Gray,et al. Pharmacokinetics of drugs that inactivate metabolic enzymes. , 1991, Journal of pharmaceutical sciences.
[57] A. Goldsobel. TERFENADINE-KETOCONAZOLE INTERACTION: PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES , 1994, Pediatrics.
[58] Rodrigues Ad,et al. Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .
[59] A. D. Rodrigues,et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.
[60] K. Renton,et al. Depression of the hepatic cytochrome P-450 mono-oxygenase system by administered tilorone (2,7-bis(2-(diethylamino)ethoxy)fluoren-9-one dihydrochloride). , 1976, Drug metabolism and disposition: the biological fate of chemicals.
[61] C. Flexner,et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive , 1999, Clinical pharmacology and therapeutics.
[62] K. Korzekwa,et al. Cytochromes P450 Expression Systems , 1995 .
[63] M. Strolin Benedetti,et al. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. , 1994, Environmental health perspectives.
[64] G. Bailie,et al. Quinolone-Cation Interactions: A Review , 1991, DICP : the annals of pharmacotherapy.
[65] K. Rieckmann,et al. Quinine disposition during malaria and during induced fever , 1976, Clinical pharmacology and therapeutics.
[66] A. Jounela. [Clinically important drug interactions]. , 1980, Duodecim; laaketieteellinen aikakauskirja.
[67] D. Middlemas,et al. Human Immunodeficiency Virus Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but Retain Antiviral Efficacy in Cell Lines Expressing These Transporters , 1998, Antimicrobial Agents and Chemotherapy.
[68] P. Pizzo,et al. Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.
[69] S. Krähenbühl,et al. Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.
[70] E. Buchert,et al. Clinical implications of variable antiarrhythmic drug metabolism. , 1992, Pharmacogenetics.
[71] G. Garber,et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability , 1993, Clinical pharmacology and therapeutics.
[72] J. Leonard,et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir * , 1998, Clinical pharmacology and therapeutics.
[73] P. Macdonald,et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. , 1995, The New England journal of medicine.
[74] V. Fischer,et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. , 1992, The Journal of pharmacology and experimental therapeutics.
[75] A. Li,et al. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. , 1997, Chemico-biological interactions.
[76] M. Whitelaw,et al. TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME P450 GENES BY DIFFERENT CLASSES OF CHEMICAL INDUCERS , 1998, Clinical and experimental pharmacology & physiology.
[77] J. McElnay,et al. Protein Binding Displacement Interactions and their Clinical Importance , 1983, Drugs.
[78] D. Greenblatt,et al. In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.
[79] F. Vallée,et al. Effects of Rifabutin and Rifampicin on the Pharmacokinetics of Ethinylestradiol and Norethindrone , 1998, Journal of clinical pharmacology.
[80] A. Renwick,et al. Factors affecting the absolute bioavailability of nifedipine. , 1995, British journal of clinical pharmacology.
[81] Bruce L. Miller,et al. Office of Technology Assessment Task Force , 1991 .
[82] K. Ruckpaul,et al. Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[83] S. Surapureddi,et al. Hepatocyte Nuclear Factor 4α Regulates Rifampicin-Mediated Induction of CYP2C Genes in Primary Cultures of Human Hepatocytes , 2010, Drug Metabolism and Disposition.
[84] J. Graybill,et al. Itraconazole-didanosine excipient interaction. , 1993, JAMA.
[85] R. Fontana,et al. Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[86] M. Tonini,et al. Recent advances in the pharmacology of gastrointestinal prokinetics. , 1996, Pharmacological research.
[87] B. Ring,et al. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.
[88] W. Stein,et al. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. , 1997, Physiological reviews.
[89] S. Safrin,et al. Interactions and toxicities of drugs used in patients with AIDS. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] R. Owens,et al. Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[91] J. Brockmöller,et al. Assessment of Liver Metabolic Function , 1994, Clinical pharmacokinetics.
[92] A. Guillouzo,et al. Caffeine and theophylline metabolism in newborn and adult human hepatocytes; comparison with adult rat hepatocytes. , 1988, Biochemical pharmacology.
[93] T. Futami,et al. Effect of clarithromycin on renal excretion of digoxin: Interaction with P‐glycoprotein , 1998, Clinical pharmacology and therapeutics.
[94] Alessio Fasano,et al. Tight junction modulation and its relationship to drug delivery. , 2006, Advanced drug delivery reviews.
[95] E. Morgan,et al. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. , 1997, Biochemical pharmacology.
[96] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[97] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[98] U. Klotz,et al. Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.
[99] U. Christians,et al. Grapefruit Juice Activates P-Glycoprotein-Mediated Drug Transport , 1999, Pharmaceutical Research.
[100] Kirby Wm,et al. Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients. , 1971 .
[101] B. Tang,et al. Variability of acetaminophen metabolism in Caucasians and Orientals. , 1992, Pharmacogenetics.
[102] H. Saitoh,et al. Restricted Intestinal Absorption of Some β-Lactam Antibiotics by an Energy-Dependent Efflux System in Rat Intestine , 1997, Pharmaceutical Research.
[103] Leslie Z. Benet,et al. Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat , 1998, Pharmacology.
[104] T. Jones. The Use of Other Drugs to Allow a Lower Dosage of Cyclosporin to Be Used , 1997, Clinical pharmacokinetics.
[105] P. Watkins,et al. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[106] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[107] E. Morgan,et al. Regulation of cytochrome P450IIC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone. , 1991, Molecular pharmacology.
[108] P. Statkevich,et al. Renal Disposition and Drug Interaction Screening of (–)-2′-deoxy-3′-thiacytidine (3TC) in the Isolated Perfused Rat Kidney , 1995, Pharmaceutical Research.
[109] G. Park,et al. Failure of critically ill patients to metabolise midazolam , 1987, Anaesthesia.
[110] M. Rowland. Plasma Protein Binding and Therapeutic Drug Monitoring , 1980, Therapeutic drug monitoring.
[111] R. Polk. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. , 1989, The American journal of medicine.
[112] R. Bendayan. Renal Drug Transport: A Review , 1996, Pharmacotherapy.
[113] Dale J. Kempf,et al. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.
[114] K. Giacomini,et al. Role of organic cation transporters in drug absorption and elimination. , 1998, Annual review of pharmacology and toxicology.
[115] S. Krähenbühl,et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. , 1998, British journal of clinical pharmacology.
[116] W. Pierson,et al. Altered theophylline clearance during an influenza B outbreak. , 1982, Pediatrics.
[117] P. Dogterom. Development of a simple incubation system for metabolism studies with precision-cut liver slices. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[118] C. Regårdh,et al. Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men , 1997, European Journal of Clinical Pharmacology.
[119] T. Hidaka,et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. , 1998, International journal of clinical pharmacology and therapeutics.
[120] R. Farinotti,et al. Absorption of ofloxacin isomers in the rat small intestine , 1997, Antimicrobial agents and chemotherapy.
[121] S. Strom,et al. Use of human hepatocytes to study P450 gene induction. , 1996, Methods in enzymology.
[122] E. Morgan. Regulation of cytochromes P450 during inflammation and infection. , 1997, Drug metabolism reviews.
[123] T. D. Bell,et al. ALTERED THEOPHYLLINE PHARMACOKINETICS DURING ACUTE RESPIRATORY VIRAL ILLNESS , 1978, The Lancet.
[124] H. Bonkovsky,et al. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. , 1985, Gastroenterology.
[125] T. Ludden. Pharmacokinetic Interactions of the Macrolide Antibiotics , 1985, Clinical pharmacokinetics.
[126] D. Greenblatt,et al. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. , 1987, Arzneimittel-Forschung.
[127] D. Greenblatt,et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences , 1998, Clinical pharmacology and therapeutics.
[128] Y. Yazaki,et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole , 1998, Hematological oncology.
[129] Ichikawa Yoshiyuki,et al. Interleukin 2 induction of cytochrome P450-linked monooxygenase systems of rat liver microsomes , 1993 .
[130] R. Weintraub,et al. Drug Interactions with Grapefruit Juice , 1997, Clinical pharmacokinetics.
[131] S. Ekins,et al. Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[132] G. Farrell,et al. Inhibition of antipyrine metabolism by interferon. , 1986, British journal of clinical pharmacology.
[133] W. Rubas,et al. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. , 1997, Critical reviews in therapeutic drug carrier systems.
[134] R. Barbhaiya,et al. A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic. , 1997, Biopharmaceutics & drug disposition.
[135] P. Hansten. Drug interactions with antisecretory agents , 1991, Alimentary pharmacology & therapeutics.
[136] L. Bertilsson,et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. , 1994, British journal of clinical pharmacology.
[137] L. Wang,et al. Human thiopurine S‐methyltransferase (TPMT) pharmacogenetics: Variant allozyme aggresome formation , 2005 .
[138] D W Nebert,et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.
[139] S. Sriwiriyajan,et al. Effect of omeprazole on the pharmacokinetics of itraconazole , 1998, European Journal of Clinical Pharmacology.
[140] P. Bonate,et al. Drug Interactions at the Renal Level , 1998, Clinical pharmacokinetics.
[141] P. Beaune,et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. , 1999, Biochemical pharmacology.
[142] E. Schuetz,et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.
[143] G. L. Kedderis. Pharmacokinetics of drug interactions. , 1997, Advances in pharmacology.
[144] N. Kitteringham,et al. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.
[145] C. L. Ferguson,et al. Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.
[146] H. Bonkovsky,et al. Cytochrome P450 of small intestinal epithelial cells , 1985 .
[147] F. Guengerich,et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[148] J. Lettieri,et al. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding , 1989, Antimicrobial Agents and Chemotherapy.
[149] Elizabeth Landrum Michalets,et al. Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.
[150] M. Viitasalo,et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia , 2004, European Journal of Clinical Pharmacology.
[151] B. Hasinoff,et al. Iron supplements: a common cause of drug interactions. , 1991, British journal of clinical pharmacology.
[152] L. Corcos,et al. Interleukin‐1β antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture , 1995 .
[153] O Pelkonen,et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[154] Morton B. Brown,et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.
[155] E. De Clercq,et al. Carrier Mechanisms Involved in the Transepithelial Transport of bis(POM)-PMEA and Its Metabolites Across Caco-2 Monolayers , 1998, Pharmaceutical Research.
[156] F. Steinhäuslin,et al. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. , 1992, British journal of clinical pharmacology.
[157] M. Lennard. Genetically Determined Adverse Drug Reactions Involving Metabolism , 1993, Drug safety.
[158] Akira Tsuji,et al. Carrier-Mediated Intestinal Transport of Drugs , 1996, Pharmaceutical Research.
[159] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[160] J. Silverman,et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. , 1998, The Journal of pharmacology and experimental therapeutics.
[161] D. Sadowski. Drug Interactions with Antacids , 1994, Drug safety.
[162] P. Neuvonen,et al. Interference of Iron with the Absorption of Tetracylines in Man , 1970, British medical journal.
[163] P. Neuvonen,et al. Itraconazole increases plasma concentrations of quinidine , 1997, Clinical pharmacology and therapeutics.
[164] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[165] G. Wormser,et al. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis , 1992, The Lancet.
[166] G. Farrell,et al. Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. , 1989, Gastroenterology.
[167] W. Ritschel. Handbook of basic pharmacokinetics , 1976 .
[168] R. O'Reilly. Interaction of sodium warfarin and rifampin. Studies in man. , 1974, Annals of internal medicine.
[169] Sack Rb. Letter: Serotyping of E. coli. , 1976, Lancet.
[170] P. Welling. Interactions Affecting Drug Absorption , 1984, Clinical pharmacokinetics.
[171] R. Hunt,et al. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. , 1990, Gastroenterology.
[172] J. Miners,et al. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[173] R. Bendayan,et al. Interaction of 3′‐Azido‐3′‐Deoxythymidine With the Organic Base Transporter in a Cultured Renal Epithelium , 1995, Pharmacotherapy.
[174] I. Fong,et al. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole , 1995, Antimicrobial agents and chemotherapy.
[175] R. Blouin,et al. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. , 1993, British journal of clinical pharmacology.
[176] D. Greenblatt,et al. Drug interactions with newer antidepressants: role of human cytochromes P450. , 1998, The Journal of clinical psychiatry.
[177] A. Y. Lu. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[178] J. Leyden,et al. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. , 1985, Journal of the American Academy of Dermatology.
[179] R. Weinshilboum. Methyltransferase pharmacogenetics. , 1989, Pharmacology & therapeutics.
[180] T. Seki,et al. Depression of drug metabolizing activity in the human liver by interferon-α , 2004, European Journal of Clinical Pharmacology.
[181] H. Dowling,et al. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. , 1951, A.M.A. archives of internal medicine.
[182] R. Parsons,et al. Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes. , 1975, Journal of Antimicrobial Chemotherapy.
[183] P. Rolan. Plasma protein binding displacement interactions--why are they still regarded as clinically important? , 1994, British journal of clinical pharmacology.
[184] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[185] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[186] J. Metcalf,et al. Alteration in Indinavir Clearance During Interleukin‐2 Infusions in Patients Infected with the Human Immunodeficiency Virus , 1998, Pharmacotherapy.
[187] Shiyin Yee,et al. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.
[188] B. Krevsky,et al. Regional differences in gastric acidity and antacid distribution: is a single pH electrode sufficient? , 1997, The American journal of gastroenterology.
[189] S. Spielberg,et al. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[190] Kathy Carroll,et al. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.
[191] F. Guengerich. Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.
[192] A. Parkinson. An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.
[193] J. Smart,et al. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. , 1998, Toxicology letters.
[194] S. Loft,et al. Antipyrine clearance in pneumonia , 1985, Clinical pharmacology and therapeutics.